BioArctic Website, Blog & Press Pages

BioArctic Website, Blog & Press Pages - aVenture Research

Library

bioarctic.comCrawled Oct 27, 2026

Press

6 pages

BioArctic AB intends to list on Nasdaq Stockholm/en/bioarctic-ab-intends-to-list-on-nasdaq-stockholm-ipo
BioArctic enters into Collaboration with AbbVie for Parkinson’s Disease Research/en/bioarctic-enters-into-collaboration-with-abbvie-for-parkinsons-disease-research
BioArctic and AbbVie collaborated to develop and commercialize BioArctic’s antibodies targeting alpha-synuclein for Parkinson’s disease and other potential uses.
BioArctic Neuroscience and Elos Medtech start collaboration on new treatment for spinal cord injuries/en/bioarctic-neuroscience-and-elos-medtech-start-collaboration-on-new-treatment-for-spinal-cord-injuries
The Swedish biotech company BioArctic Neuroscience and the medtech company Elos Medtech have today signed a cooperation agreement for a new treatment of spinal cord injuries.
BioArctic Neuroscience and Swenora Biotech Enter into exclusive licensing agreement/en/bioarctic-neuroscience-and-swenora-biotech-enter-into-exclusive-licensing-agreement
BioArctic Neuroscience and Swenora Biotech entered an exclusive licensing agreement, granting BioArctic global rights to develop and market a spinal cord injury treatment.

Team

2 pages

Nomination Committee 2018/en/nomination-committee-2018
BioArctic AB’s 2017 Annual General Meeting resolved that the 2018 Nomination Committee members would be selected from the three largest shareholders, as recorded by Euroclear on September 30, 2017.
Nomination Committee 2019/en/nomination-committee-2019
BioArctic AB’s 2018 Annual General Meeting resolved that the 2019 Nomination Committee members would be selected from the three largest shareholders, as recorded by Euroclear on September 30, 2018.

Homepage

1 page

bioarctic.com/

Coverage

5 items

BioArctic collaborator Novartis terminates agreementbioarctic.com/en/bioarctic-collaborator-novartis-terminates-agreement/
Novartis terminates its agreement with BioArctic to explore a potential treatment combining BioArctic’s BrainTransporter™ technology with an undisclosed Novartis antibody. The partnership, initiated in August 2025, aimed to develop a new therapeutic approach. BioArctic announces the termination in a public statement, marking the end of the collaboration.
Nov 2026BioArcticNews article
First patient treated with Leqembi® (lecanemab) in Swedenbioarctic.com/en/first-patient-treated-with-leqembi-lecanemab-in-sweden/
BioArctic AB begins offering Leqembi (lecanemab) at a private Swedish clinic, marking the first patient treated outside clinical trials since the drug’s EU approval in April 2025. Leqembi, an Alzheimer’s therapy, is now available for patients in Sweden beyond controlled study settings. The company highlights this milestone as a step toward broader accessibility for eligible individuals.
Sep 2026BioArcticNews article
Leqembi® Pen subcutaneous formulation approved in Japanbioarctic.com/en/leqembi-pen-subcutaneous-formulation-approved-in-japan/
Eisai, in partnership with BioArctic, receives regulatory approval in Japan for Leqembi Pen, a subcutaneous autoinjector formulation of Leqembi. This new administration method targets early-stage Alzheimer’s disease treatment. The approval expands treatment options for patients in Japan.
Sep 2026BioArcticNews article
BioArctic and Mesenkia enter oncology research collaborationbioarctic.com/en/bioarctic-and-mesenkia-enter-oncology-research-collaboration/
BioArctic and Mesenkia Therapeutics collaborate on a research agreement to develop an antibody-based treatment for glioblastoma. The partnership targets overcoming challenges in delivering large molecules to the brain for this aggressive cancer type. Both companies aim to leverage novel approaches in oncology research.
Aug 2026BioArcticNews article